The new venture, called MBX Biosciences Inc., aims to develop therapeutics to treat rare endocrine disorders. The company has already raised $2.5 million in funding.
Promising Lilly cancer drug fails in disappointing trial, shares fall 3 percent
Analysts had predicted that Lartruvo could eventually ring up as much as $600 million in annual sales. Eli Lilly and Co. now says it will suspend promotion of the drug.Read More
The drug rebate rule would have ended a widespread practice in which drugmakers give rebates to insurance middlemen in government programs such as Medicare. The idea was to channel that money to consumers instead.
Lilly shares dropped 4.6 percent in early trading after the company said Christi Shaw was leaving and Mike Harrington planned to retire.
Responding to a lawsuit by Eli Lilly and two other companies, a federal judge Monday blocked a major White House initiative on prescription drug costs, saying the Trump administration lacked the legal authority to require drugmakers to disclose their prices in TV ads.
Patricia Martin, 58, former chief operating officer of Lilly’s diabetes division, will start her new job July 1, leading an organization that promotes and invests in the state’s life sciences sector.
Array’s stock was already at a record before the deal announcement, following the company’s news last month of positive clinical trial results using Braftovi and Mektovi with Indianapolis-based Eli Lilly and Co.’s Erbitux.
Some of the biggest pharmaceutical companies, including Indianapolis-based Eli Lilly and Co., sued the Trump administration to try and block a rule that would force them to put the price of their drugs in television advertisements.
“Our central focus as a company is always to make lives better. … It’s a value that is core to every single employee who works here. So if we can have programs that reinforce that we are a company that is focused on making lives better, then we are doing something that connects to our mission and reminds our employees what really matters to us as a company.”
It’s the second approved use for Emgality, which first won U.S. approval last fall to treat migraines. Analysts predict it could become a blockbuster.
After one of its largest listed drug makers was found to have overstated its cash position by $4.3 billion, China is starting an audit of 77 major pharmaceutical companies.
The fast-acting insulin, which diabetics inject shortly before each meal, is used by about 700,000 Americans.
Indianapolis-based Lilly reported first quarter revenue of $5.09 billion, up 3% from a year ago but below analyst expectations of $5.2 billion. Sales of several of Lilly’s top drugs missed expectations.
Local tech firm, Springbuk, has grown from 16 to 102 employees in a little more than two years. A recently released product upgrade the company is calling “a game changer” is spurring another round of serious growth.
Paul Elmer, former owner and CEO of Pharmakon Pharmaceuticals in Noblesville, was convicted in federal court of nine counts of adulterating drugs and one count of conspiracy. He was acquitted of an additional count of obstruction of justice.
As Congress and President Donald Trump's administration aim to lower prescription drug costs, outside groups like the Alliance for Patient Access are seeking to sway the outcome.
The proposed tax abatement is related to a $91 million investment the company is making in a building at the Lilly Technology Center on Kentucky Avenue.
The state’s largest health system said earnings from operations climbed 4 percent, but investment losses pulled down total earnings by 70 percent.
The suit accuses the companies of raising insulin sticker prices by more than 150 percent over five years, forcing diabetics to forgo the drug, take less insulin than needed or use expired versions